Christine L. Boutros

This paper uses humanized mice to study how HIV resistance to broadly neutralizing antibodies (bNAbs) affects the efficacy of AAV-delivered immunotherapy, finding that escape mutation fitness costs and resistance benefits determine therapeutic success.

The paper identifies LY6A as a novel receptor for AAV-PHP.B vectors, enabling efficient gene delivery across the blood-brain barrier in mice.